Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) Overview | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) Products under Development by Stage of Development | 7 | 1 |
| Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) Products under Development by Therapy Area | 8 | 1 |
| Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) Products under Development by Indication | 9 | 1 |
| Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) Pipeline Products Glance | 10 | 2 |
| Late Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) Products under Development by Companies | 12 | 2 |
| Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) Products under Development by Universities/Institutes | 14 | 2 |
| Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) Therapeutics Assessment | 16 | 6 |
| Assessment by Monotherapy/Combination Products | 16 | 1 |
| Assessment by Mechanism of Action | 17 | 1 |
| Assessment by Route of Administration | 18 | 2 |
| Assessment by Molecule Type | 20 | 2 |
| Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) Companies Involved in Therapeutics Development | 22 | 4 |
| Cerecor Inc. | 22 | 1 |
| CureVac GmbH | 23 | 1 |
| Eisai Co., Ltd. | 24 | 1 |
| Inovio Pharmaceuticals, Inc. | 25 | 1 |
| Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) Drug Profiles | 26 | 7 |
| CV-9103 Drug Profile | 26 | 2 |
| E-2072 Drug Profile | 28 | 1 |
| INO-5150 Drug Profile | 29 | 1 |
| Small Molecule for Neuropathic Pain Drug Profile | 30 | 1 |
| Small Molecule to Inhibit Glutamate Carboxypeptidase 2 for Cognitive Impairment and Memory Impairment Drug Profile | 31 | 1 |
| Vaccine to Target Prostate Specific Membrane Antigen for Renal Cell Carcinoma Drug Profile | 32 | 1 |
| Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) Dormant Projects | 33 | 2 |
| Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) Discontinued Products | 35 | 1 |
| Glutamate Carboxypeptidase 2 (Folate Hydrolase or Prostate Specific Membrane Antigen or PSMA or Pteroylpoly-Gamma-Glutamate Carboxypeptidase or EC 3.4.17.21) Featured News &Press Releases | 36 | 8 |
| Jul 27, 2015: Inovio Pharmaceuticals Initiates Clinical Trial of INO-5150 DNA Immunotherapy for Prostate Cancer | 36 | 1 |
| Jul 07, 2015: CureVac Announces Phase I/IIa Clinical Study Data of its mRNA Cancer Immunotherapy in Prostate Cancer Published in the Journal for ImmunoTherapy of Cancer | 36 | 1 |
| Nov 19, 2012: Experimental Drug Improves Memory In Mice With Multiple Sclerosis, Researchers Report | 37 | 2 |
| Jun 10, 2011: CureVac Presents Promising New Data For Prostate Cancer Vaccine CV9103 At ASCO Conference | 39 | 1 |
| Feb 02, 2011: Inovio's Dual-Antigen SynCon DNA Vaccine For Prostate Cancer Induces Robust Responses In Preclinical Trial | 40 | 1 |
| Oct 04, 2010: CureVac Presents Data From Phase I/IIa Clinical Study With CV9103 In Hormone-Refractory Prostate Cancer | 40 | 1 |
| Nov 02, 2009: CureVac Launches Phase IIa mRNA Vaccine Trial In Prostate Cancer | 41 | 1 |
| May 01, 2009: CureVac Receives FDA Approval to Start its Phase I / IIa Trial in the U.S. with an mRNA Vaccine for the Treatment of Prostate Cancer | 41 | 1 |
| Jan 05, 2009: CureVac Receives IND Approval From FDA To Start Its Phase I/IIa mRNA Vaccine Clinical Trial In Prostate Cancer | 42 | 1 |
| Oct 12, 2008: CureVac to Start First mRNA Vaccine Clinical Trial in Prostate Cancer | 43 | 1 |
| Appendix | 44 | 2 |
| Methodology | 44 | 1 |
| Coverage | 44 | 1 |
| Secondary Research | 44 | 1 |
| Primary Research | 44 | 1 |
| Expert Panel Validation | 44 | 1 |
| Contact Us | 44 | 1 |
| Disclaimer | 45 | 1 |